

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Nivolumab for treating metastatic or unresectable urothelial cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

| |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

| |
|----------------------------|
| No issues were identified. |
|----------------------------|

| |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

| |
|-----|
| N/A |
|-----|

| |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

| |
|-----|
| N/A |
|-----|

| |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
|--|

| |
|---|
| No additional stakeholders were identified. |
|---|

Approved by Associate Director (name): Helen Knight

Date: 26/04/2017

Technology Appraisals: Scoping

Equality impact assessment for the Single Technology Appraisal of nivolumab for treating metastatic or unresectable urothelial cancer

Issue date: April 2017